現在価格
$1008.27
競争上のモート
↑Patent Protection on Key Drugs
Lilly benefits from strong patent protection on drugs like Trulicity and Mounjaro. This exclusivity allows for premium pricing and market share dominance before generics enter.
↑Established Brand Reputation in Diabetes Care
Lilly has cultivated a strong brand in diabetes, fostering physician and patient loyalty. This reputation provides a competitive edge in a growing market.
↑Pipeline of Innovative Therapies
Lilly's robust pipeline, particularly in Alzheimer's and obesity, offers future growth potential. Successful drug launches will further solidify their market position.
投資リスク
↓Patent Expirations and Generic Competition
Loss of exclusivity on key drugs will significantly impact revenue. Lilly must successfully launch new products to offset these losses and maintain growth.
↓Clinical Trial Failures and Regulatory Hurdles
Drug development is inherently risky, and clinical trial failures are common. Regulatory delays or rejections can significantly impact pipeline value.
↓Pricing Pressure and Reimbursement Challenges
Increasing pressure from payers to lower drug prices could erode profitability. Changes in reimbursement policies could limit access to Lilly's therapies.
AI の洞察を DCF または PE 株式バリュエーションと組み合わせて、内在価値を計算。データに基づくより良い株式バリュエーション判断を。
本ページでは、Eli Lilly and Company (LLY) の AI 駆動による株式バリュエーション洞察を、競争上のモートと投資リスク要因を含めて提供します。株式バリュエーションは健全な投資判断の中核です — MiniValuator の DCF と PE 株式バリュエーションツールをこれらの AI 洞察と併用して、LLY の内在価値と安全マージンを計算し、十分な根拠のある株式バリュエーション判断を導いてください。